The Magazine for Sleep Professionals
Saturday, June 13, 2026
Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of […]
Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]
New survey results from the American Academy of Sleep Medicine explore the complex relationship between marijuana use and sleep. One-third (33%) of adults reported that their sleep is slightly or significantly better when they use marijuana. In contrast, 19% of adults reported either no impact (11%) or that their sleep is […]
Staying active is known to improve sleep, but the research findings are mixed regarding the best workout. Some studies say light walking or stretching is best, others prefer moderate-intensity workouts like jogging — and some even find that vigorous exercise such as swimming makes sleep worse. Resolving this discrepancy is […]
Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026. The study, titled: “Modulating […]
A new national survey from Imagine360, a leading alternative health plan for self-funded employers, reveals a rising healthcare affordability crisis with 1 in 3 insured Americans saying they’re losing sleep over the cost of care. As employer-sponsored healthcare costs climb to record highs, nearly half (44%) of survey respondents are […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Narcolepsy is a chronic condition in which someone feels excessively sleepy, occasionally falling asleep without warning. This can have a major impact on their daily lives, affecting not only their education and employment, but also their ability to drive, their relationships, and their emotional health. “It’s quite striking when you’re […]
University of Texas at Dallas researchers, in partnership with Texas-based biotech company EnLiSense, have demonstrated a pioneering wearable perspiration-based sensor that measures two key hormones that regulate the body’s sleep-wake cycle. The electrochemical sensor continuously monitors cortisol, which promotes wakefulness, and melatonin, which signals the body to sleep. The bioengineers […]
